RxDoctor Payments Data

Michael Scharf, MD

Internal Medicine · Liberty Township, OHNPI 1609868744

Payments from drug & device makers

$4,502in general payments, 2019–2025

Across 157 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$617
  • Johnson & Johnson$506
  • GSK$392
  • Amgen$336
  • Novo Nordisk$197
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,488100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,502 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$43,160
Medicare patients
215
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide48$91,035
JardianceEmpagliflozin44$58,500
OzempicSemaglutide48$51,376
FarxigaDapagliflozin Propanediol23$32,155
JanuviaSitagliptin Phosphate20$27,599
XareltoRivaroxaban16$25,794
TradjentaLinagliptin13$14,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,555
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,339
Atorvastatin Calcium448$3,051
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,576
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,377
Levothyroxine Sodium191$1,685
Ezetimibe52$1,564
Rosuvastatin Calcium105$1,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$113$91,03548 claims
Boehringer IngelheimJardiance, Tradjenta$99$73,37157 claims
Novo NordiskOzempic$197$51,37648 claims
AstraZenecaFarxiga$1,257$32,15523 claims
MerckJanuvia$50$27,59920 claims
Johnson & JohnsonXarelto$506$25,79416 claims
GSKTrelegy Ellipta$392$11,55518 claims
AbbVieSynthroid$617$42424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Liberty Township

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →